Approval · Notice of Compliance 36897 · 2026
ZEPBOUND: Notice of Compliance 36897
Issued February 12, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36897
- Date
- February 12, 2026
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in product name. Product Monograph reformatted to the Master Template. Update to Instructions for Use. New package labels. Update to package insert
Products in this notice
Medicinal ingredients
- TIRZEPATIDE 2.5 MG per 0.6ML
- TIRZEPATIDE 5 MG per 0.6ML
- TIRZEPATIDE 7.5 MG per 0.6ML
- TIRZEPATIDE 10 MG per 0.6ML
- TIRZEPATIDE 12.5 MG per 0.6ML
- TIRZEPATIDE 15 MG per 0.6ML